⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL486558 | 0.81 | — | — | |
| SCHEMBL29443091 | 0.77 | — | — | |
| SCHEMBL530450 | 0.77 | — | — | |
| SCHEMBL1777496 | 0.72 | — | — | |
| SCHEMBL30598347 | 0.72 | S100A4 (0.46) | — | |
| SCHEMBL23638850 | 0.72 | S100A4 (0.46) | — | |
| SCHEMBL660048 | 0.72 | — | — | |
| 2,5-Dichlorofluorobenzene SCHEMBL29707637 | 0.72 | — | — | |
| 2,5-Dichlorofluorobenzene SCHEMBL529850 | 0.72 | — | — | |
| SCHEMBL3606294 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4795952-B2 | — | — | 2011-10-19 | — | — | JP | claimed |
| US-20090312343-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | HENNEQUIN LAURENT FRANCOIS AND | 2009-12-17 | — | — | US | claimed |
| EP-1667996-B1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2009-07-22 | — | — | EP | claimed |
| EP-1667991-B1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2008-05-14 | — | — | EP | claimed |
| US-7268137-B2 | Ocular therapy | NOVARTIS AG (CH) | 2007-09-11 | — | — | US | claimed |
| JP-2007506696-A | — | — | 2007-03-22 | — | — | JP | claimed |
| JP-2007505872-A | — | — | 2007-03-15 | — | — | JP | claimed |
| US-20070060582-A1 | 1,4-Disubstituted isoquinilone derivatives as raf-kinase inhibitors useful for the treatment of proliferative diseases | FINK CYNTHIA A | 2007-03-15 | — | — | US | claimed |
| US-20070043009-A1 | Quinazoline derivatives as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2007-02-22 | — | — | US | claimed |
| US-20070032513-A1 | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2007-02-08 | — | — | US | claimed |
| US-20050209238-A1 | Method for treating ocular neovascular diseases | BRAZZELL ROMULUS K | 2005-09-22 | — | — | US | claimed |
| WO-2005028444-A1 | 1,4-DISUBSTITUTED ISOQUINILONE DERIVATIVES AS RAF-KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2005-03-31 | — | — | WO | claimed |
| WO-2005026150-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2005-03-24 | — | — | WO | claimed |
| WO-2005026157-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2005-03-24 | — | — | WO | claimed |
| US-20040116434-A1 | Ocular therapy | NOVARTIS AG (CH) | 2004-06-17 | — | — | US | claimed |
| US-20040102444-A1 | Method for delivering drugs to the retina | CAMPOCHIARO PETER (US) | 2004-05-27 | — | — | US | claimed |
| US-20030171375-A1 | Method for treating ocular neovascular diseases | NOVARTIS AG (CH) | 2003-09-11 | — | — | US | claimed |
| US-6271233-B1 | ADMINISTERING PHTHALAZINE DERVIVATIVES FOR TREATMENT AND PREVENTION OF RETINAL AND CHOROIDAL NEOVASCULARIZATION, EXUDATIVE AGE RELATED MACULAR DEGENERATION, PROLIFERATIVE DIABETIC RETINOPATHY, AND/OR ISCHEMIC RETINOPATHIES | CIBA VISION CORPORATION | 2001-08-07 | — | — | US | claimed |
| EP-1105136-A2 | METHOD FOR TREATING OCULAR NEOVASCULAR DISEASES | Novartis AG (CH) | 2001-06-13 | — | — | EP | claimed |
| WO-2000009098-A2 | METHOD FOR TREATING OCULAR NEOVASCULAR DISEASES | NOVARTIS AG (CH) | 2000-02-24 | — | — | WO | claimed |